Episode Details
Back to Episodes
Pharmaceutical Executive Daily: FDA Grants Accelerated Approval to Rybrevant Faspro
Published 1 week, 5 days ago
Description
Hims & Hers partners with Eli Lilly to sell Zepbound and Foundayo directly on its platform, Novo Nordisk terminates its research collaboration with Korro Bio, and the FDA grants accelerated approval to Johnson & Johnson’s Rybrevant Faspro in head and neck cancer.